Format

Send to

Choose Destination
Womens Health (Lond). 2015 Nov;11(6):749-57. doi: 10.2217/whe.15.68. Epub 2015 Dec 2.

Long-acting hormonal contraception.

Author information

1
Department of Gynecology, Obstetrics & Urology, University of Rome, Viale del Policlinico 155, 00161 Roma, Italy.
2
Department of Obstetrics & Gynecology, Eastern Virginia Medical School, 700 W Olney Rd, Norfolk, VA 23507, USA.
3
Leuven Institute for Fertility & Embryology, 3000 Leuven, Belgium.

Abstract

Today, a new category of fertility-regulating agents has been created: long-acting, reversible hormonal contraceptives; they minimize compliance, while maximize effectiveness. They comprise subdermal implants and intrauterine devices. Other long-acting agents exist, such as Depo Provera and Noristerat. Use of Depo Provera and Noristerat carries great effectiveness, good clinical safety and usefulness in developing countries. They cause no significant increase in breast cancer risk, but they may carry an increased risk of HIV. Subcutaneous delivery systems have two common features: prolongation of effect is obtained by a drug reservoir and for most of their duration of action they provide a continuous, sustained release of the active hormone. Finally, the intrauterine system Mirena represents both a very effective contraceptive and a specific treatment for menorrhagia.

KEYWORDS:

Depot–Depo Provera; Implanon; Jadelle; Mirena; Noristerat; Uniplant; injectable contraceptives; intrauterine contraceptive systems; long-acting contraceptives; subcutaneous contraceptive implants

PMID:
26626534
DOI:
10.2217/whe.15.68
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center